JP Morgan Downgrades Vir Biotechnology to Neutral, Lowers Price Target to $9
Benzinga · 01/29 11:06
JP Morgan analyst Eric Joseph downgrades Vir Biotechnology (NASDAQ:VIR) from Overweight to Neutral and lowers the price target from $23 to $9.